Formycon Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Stefan Glombitza

İcra Kurulu Başkanı

€612.3k

Toplam tazminat

CEO maaş yüzdesi	57.2%
CEO görev süresi	8.6yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.9yrs
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

Expected Launches Of Stelara And Keytruda Biosimilars Will Strengthen Future Pipeline

Jan 18 The launch of biosimilars and strategic focus on high-growth areas indicate strong future revenue and earnings potential for Formycon.

We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) Earnings

Nov 05

We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash Wisely

Sep 04

Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)

Jul 13

Bearish: Analysts Just Cut Their Formycon AG (ETR:FYB) Revenue and EPS estimates

Jun 02

Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn Situation

May 23

Here's Why We're Not At All Concerned With Formycon's (ETR:FYB) Cash Burn Situation

Feb 01

We Think Formycon (ETR:FYB) Can Easily Afford To Drive Business Growth

Sep 25

We're Interested To See How Formycon (ETR:FYB) Uses Its Cash Hoard To Grow

May 19

Is Formycon's (ETR:FYB) 179% Share Price Increase Well Justified?

Jan 04

CEO Tazminat Analizi

Stefan Glombitza'un ücretlendirmesi Formycon'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2024	€612k	€350k	-€126m
Sep 30 2024	n/a	n/a	-€31m
Jun 30 2024	n/a	n/a	€64m
Mar 31 2024	n/a	n/a	€70m
Dec 31 2023	€582k	€350k	€76m
Sep 30 2023	n/a	n/a	€17m
Jun 30 2023	n/a	n/a	-€42m
Mar 31 2023	n/a	n/a	-€3m
Dec 31 2022	€2m	n/a	€36m
Sep 30 2022	n/a	n/a	€57m
Jun 30 2022	n/a	n/a	€77m
Mar 31 2022	n/a	n/a	€32m
Dec 31 2021	€617k	n/a	-€13m

Tazminat ve Piyasa: Stefan 'ın toplam tazminatı ($USD 692.65K ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 991.35K ).

Tazminat ve Kazançlar: Stefan şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Stefan Glombitza (59 yo)

8.6yrs

Görev süresi

€612,300

Tazminat

Dr. Stefan Glombitza has been Member of Executive Board at Formycon AG since October 1, 2016 and its Chief Executive Officer since July 01, 2022. Dr. Glombitza serves as Chief Operating Officer of Formycon...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stefan Glombitza	CEO, COO & Chair of the Executive Board	8.6yrs	€612.30k	Veri yok
Nicolas Combe	Co-Founder	no data	Veri yok	Veri yok
Enno Spillner	CFO & Member of the Executive Board	2.1yrs	€560.90k	Veri yok
Andreas Seidl	Chief Scientific Officer & Member of the Executive Board	2.8yrs	€339.50k	Veri yok
Nicola Mikulcik	Chief Business Officer & Member of the Executive Board	2.9yrs	€393.80k	Veri yok
Friedrich-Wilhelm Steinweg	Co-Founder	no data	Veri yok	Veri yok
Sabrina Muller	Director of Investor Relations & Corporate Communications	no data	Veri yok	Veri yok

2.9yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: FYB 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Colin Bond	Independent Deputy Chairman of the Supervisory Board	less than a year	€22.50k	Veri yok
Nicholas Haggar	Independent Member of the Supervisory Board	less than a year	€35.80k	Veri yok
Klaus Rohrig	Member of the Supervisory Board	4.4yrs	€39.00k	Veri yok
Wolfgang Essler	Chairman of the Supervisory Board	1.8yrs	€67.80k	Veri yok
Bodo Coldewey	Independent Member of the Supervisory Board	less than a year	€29.30k	Veri yok

0.9yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: FYB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.9 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/07 16:42
Gün Sonu Hisse Fiyatı	2025/05/07 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Formycon AG 15 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Gerhard Orgonas	Berenberg
Benjamin Thielmann	Berenberg
Simon Scholes	First Berlin Equity Research GmbH

Formycon Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Formycon AG Appoints Colin Bond as Director

Formycon AG Announces Supervisory Board and Executive Changes

Formycon AG Announces Changes to Its Executive Board

Formycon AG, Annual General Meeting, Sep 27, 2021

Recent updates

Price target decreased by 8.4% to €49.56

Full year 2024 earnings released: €7.19 loss per share (vs €4.76 profit in FY 2023)

Formycon AG Provides Earnings Guidance for the Year 2025

Consensus EPS estimates upgraded to €2.88 loss, revenue downgraded

Price target decreased by 10% to €54.11

Consensus EPS estimates upgraded to €2.87 loss

Fresenius Kabi Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi®? (Ustekinumab-Aauz)

Consensus EPS estimates fall by 252%

Price target decreased by 15% to €74.25

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 38%

Formycon AG Announces Decision on Phase III Trial with FYB206 and Provides Update on Potential Need to Adjust the Valuation of FYB202 and FYB201

Formycon Receives EU Approval for FYB203 (Aflibercept), A Biosimilar to Eylea, Under the Brand Names Ahzantive and Baiama

Expected Launches Of Stelara And Keytruda Biosimilars Will Strengthen Future Pipeline

Formycon AG and Fresenius Kabi Announce MHRA Approval for FYB202/Otulfi (Ustekinumab), Biosimilar to Stelara

Investor sentiment improves as stock rises 15%

Now 32% overvalued after recent price rise

Formycon AG to Report Q1, 2025 Results on May 15, 2025

Consensus EPS estimates upgraded to €0.48 loss

Consensus EPS estimates upgraded to €0.56 loss

Formycon AG Appoints Colin Bond as Director

Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz)

Consensus EPS estimates upgraded to €0.70 loss

Consensus EPS estimates upgraded to €0.96 loss

First half 2024 earnings released: €0.58 loss per share (vs €0.11 profit in 1H 2023)

Now 21% undervalued

Formycon AG to Report First Half, 2024 Results on Aug 13, 2024

New minor risk - Share price stability

A Look At The Fair Value Of Formycon AG (ETR:FYB)

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 16%

Formycon AG's (ETR:FYB) Prospects Need A Boost To Lift Shares

Price target decreased by 8.7% to €87.00

We Believe Formycon's (ETR:FYB) Earnings Are A Poor Guide For Its Profitability

Formycon AG to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: EPS: €4.76 (vs €2.62 in FY 2022)

Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Price target decreased by 12% to €96.25

New minor risk - Shareholder dilution

Price target decreased by 7.9% to €103

Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.

Some Confidence Is Lacking In Formycon AG's (ETR:FYB) P/S

We Think Formycon (ETR:FYB) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

Formycon AG's (ETR:FYB) Share Price Not Quite Adding Up

First half 2023 earnings released: EPS: €0.11 (vs €6.51 in 1H 2022)

Formycon AG to Report First Half, 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 146%

Price target decreased by 8.6% to €116

Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.

Price target increased to €126

We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) Earnings

First half 2022 earnings released: EPS: €6.51 (vs €0.92 loss in 1H 2021)

Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)

Price target increased to €107

Consensus forecasts updated

We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash Wisely

Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)

Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis

Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study

Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2

Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)

Consensus revenue estimates increase by 13%

Formycon AG Announces Supervisory Board and Executive Changes

Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA

Bearish: Analysts Just Cut Their Formycon AG (ETR:FYB) Revenue and EPS estimates

Consensus revenue estimates fall by 17%

Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn Situation